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Abstract
Bloodstream infections (BSI) are a major cause of mortality, morbidity and medical cost, but few population-based studies have concom-
itantly evaluated BSI incidence and mortality. Data on BSI episodes reported to national, population-based surveillance by all clinical
microbiology laboratories in Finland during 2004–07 were linked to vital statistics. Age-, sex and microbe-speciﬁc incidence and mortal-
ity rates were calculated. During 2004–07, 33 473 BSI episodes were identiﬁed; BSI incidence increased from 147 to 168 per 100 000
population (average annual increase, 4.4%; p <0.001). Rates were highest among persons ‡65 years and <1 year, and higher among male
patients than female patients (166 versus 152 per 100 000). The most common aetiologies were Escherichia coli (27%) and Staphylococcus
aureus (13%). Among male patients, 52% of BSI were caused by gram-positive bacteria compared with 42% among female patients
(p <0.001). The overall 30-day case-fatality was 13%. Of the deaths, 32% occurred within 2 days, 70% were among people aged 65 years
or more and 33% were caused by E. coli or S. aureus infections. The BSI mortality rate increased from 19 to 22 per 100 000 (average
annual increase: 4.0%, p 0.01). Among people aged 25 years or more, the mortality rate was 1.4-fold higher in men than women (34
versus 25 per 100 000 population). Overall excess annual mortality from BSI in the population was 18 per 100 000. The substantial BSI
burden among the elderly and among adult men highlights the need for developing and implementing effective interventions, particularly
for BSI caused by E. coli and S. aureus. One-third of BSI deaths occurred early, emphasizing the importance of early identiﬁcation and
treatment.
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Introduction
Bloodstream infections (BSI) are a major cause of mortality
and healthcare cost worldwide. In the USA, septicaemia is the
tenth leading cause of death [1]. In previous population-based
studies, the incidence of BSI ranged from 123 to 190 per
100 000 population [2–5] and increases in rates have been
reported both from European countries and the USA [2,4–7].
Limited population-based information is available on the
epidemiology and outcome of BSI [2,3], as most studies
report data from single or selected hospitals [8–11]. How-
ever, population-based information on both the incidence
and mortality are needed to deﬁne the public health burden
of BSI and to improve treatment and prevention strategies.
We used data from a national, population-based laboratory
surveillance system to evaluate age-, sex- and microbe-spe-
ciﬁc incidence and mortality from BSI during 2004–07. We
also estimated the excess deaths due to BSI in the Finnish
population.
Methods
Population-based surveillance
The Health Care System in Finland (population 5.3 million) is
organized into 20 healthcare districts, with catchment popu-
lations ranging from 68 000 to 1.4 million. All clinical micro-
biology laboratories are required to notify all bacterial and
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fungal isolates from blood to the National Infectious Disease
Register. More than 95% of laboratories report electronically
the following information: specimen date, microbe, date of
birth, sex, place of residence, and each individual’s unique
national identity code. Multiple notiﬁcations of the same
microbe which contain the same national identity code are
merged into a case if they occur within 3 months of each
other.
Episode of bloodstream infection
An episode of BSI was deﬁned as bacterial species or fungus
isolated from blood culture and reported to the National
Infectious Disease Register during 2004–07; 36 268 episodes
were included in the analysis and 229 were excluded because
of invalid national identity codes or inconsistent dates. Cases
with the same national identity code but different microbes
isolated within 2 days were merged into a single episode and
classiﬁed as polymicrobial; the rest of the episodes were
monomicrobial BSI.
Outcome
Data on patients who had died (including date of death) up
to 90 days after the date of the specimen yielding the ﬁrst
positive blood culture were retrieved from the Population
Information System by linkage with the national identity
codes.
Analysis and statistics
Population data from Statistics Finland during 2004–07 were
used as denominators to calculate age-speciﬁc and sex-spe-
ciﬁc incidence rates of BSI. Average annualized incidence and
mortality rates were calculated by using the total number of
episodes, deaths, and population during 2004–07. Male-to-
female rate ratios with 95% asymptotic CI were calculated.
The age-, sex- and microbe-speciﬁc case fatality proportions
(CFPs) for BSI episodes were calculated within 30 days of
the date of blood sample conﬁrming BSI.
Categorical variables were analysed with the chi-square
test, using Yates’s correction. Statistical signiﬁcance of the
observed trends in annual incidence and mortality rates was
assessed using a Poisson regression model. To study the tim-
ing of deaths related to BSI episodes, the observed daily haz-
ard of death was calculated using the life-table method. To
assess excess (observed – expected) deaths due to BSI, the
expected daily hazard of death in the Finnish population,
adjusted for age and sex, was calculated by using 2006 data
from Statistics Finland and compared with the observed daily
hazard following a BSI episode.
Data were analysed using SPSS FOR WINDOWS, version 17.0
(Chicago, IL, USA), PASW, version 17.2 and STATA, version
9.2 (Chicago, IL, USA).
Results
During 2004–07, a total of 33 473 BSI episodes were identi-
ﬁed among 30 523 individual patients; median age was
67 years; 51% (17 094) were male. The average annualized
incidence was 159 BSI episodes per 100 000 population, with
a signiﬁcant increasing trend from 147 per 100 000 in 2004
to 168 per 100 000 in 2007 (average increase 4.4% per year,
p <0.001). Rates were highest among people ‡65 years (528)
and <1 year (514) (Table 1). Among infants <1 year and peo-
ple ‡35 years, the BSI rate was signiﬁcantly higher for male
patients than female patients; for people aged 15–34 years,
the BSI rate was signiﬁcantly higher in female patients than in
male patients.
Aetiology of BSI
Gram-positive bacteria caused 48.5% (16 233) of the BSI epi-
sodes, gram-negative bacteria caused 43.8% (14 645), other
TABLE 1. Incidence of blood-
stream infections by age and gen-
der, Finland, 2004–07 Age group
(years)
Rate of bloodstream infectionsa
(number of episodes)
Male to female
rate ratio 95% CIMale Female Total
<1 583 (694) 442 (503) 514 (1197) 1.32 1.18–1.48
1–14 35 (589) 31 (519) 33 (1117) 1.11 0.98–1.24
15–24 33 (440) 39 (495) 36 (935) 0.85 0.75–0.97
25–34 39 (513) 47 (597) 43 (1110) 0.82 0.73–0.92
35–44 70 (1025) 57 (807) 64 (1832) 1.23 1.12–1.35
45–54 128 (1981) 95 (1455) 112 (3436) 1.35 1.26–1.44
55–64 236 (3354) 168 (2440) 201 (5794) 1.41 1.33–1.48
65–74 460 (3832) 291 (2891) 368 (6723) 1.58 1.50–1.66
75–84 782 (3529) 569 (4411) 648 (7940) 1.37 1.31–1.44
‡85 1264 (1128) 824 (2261) 932 (3389) 1.53 1.43–1.65
All 166 (17094) 152 (16379) 159 (33473) 1.09 1.07–1.11
CI, conﬁdence interval.
aAverage annualized incidence rate (episodes per 100 000 population).
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bacteria (not classiﬁable by Gram stain) caused 0.1% (22)
and fungi caused 1.6% (544). Polymicrobial infections
accounted for 6.1% (2029) of episodes. Overall, the four
most common BSI aetiologies were Escherichia coli (27%),
Staphylococcus aureus (13%), coagulase-negative staphylococci
(10%) and Streptococcus pneumoniae (9%); ten microbe cate-
gories accounted for 82% of all episodes (Fig. 1). The causa-
tive agents for BSI varied by age and gender. Gram-negative
bacteria were signiﬁcantly more common among female
patients (51.7%, 8469/16 379 versus 36.1%, 6176/17 094;
p <0.001) and gram-positive were more common among
male patients (55.1%, 9414/17 094 versus 41.6%, 6819/
16 379; p <0.001). The gender difference in BSI caused by
polymicrobial infections (6.9% in male patients versus 5.1% in
female patients, p <0.001) was less prominent, and for BSI
caused by fungi there was no difference (1.8% in male
patients versus 1.5% in female patients). Escherichia coli
caused 37% (6118/16 379) of BSI among female patients and
18% (3072/17 094) among male patients (p <0.001); it was
the most frequent cause of BSI among women ‡15 years and
among men ‡65 years (Fig. 1). Staphylococcus aureus was the
causative agent in 15% (2626/17 094) of episodes among
male patients compared with 10% (1605/16 379) among
female patients (p <0.001); S. aureus was a particularly com-
mon cause among younger male patients (Fig. 1). Streptococ-
cus pneumoniae caused 10% (1655/17 094) of episodes
among male patients and 8% (1254/16 379) among female
patients (p <0.001). Group B streptococcus was a prominent
cause of BSI among infants aged <1 year (17%) and among
women aged 25–34 years (9%) (Fig. 1).
Mortality from BSI
Of the BSI episodes, 4375 were fatal within 30 days after the
ﬁrst positive blood culture was obtained (CFP, 13%). Of the
deaths, 70% (3044/4375) occurred in patients ‡65 years
(CFP, 17%). The average annualized BSI mortality rate was
20.8 deaths per 100 000 population (range by year 19.2–
21.6), with an increasing trend over time (average annual
increase 4.0%, p 0.01). As the annual CFP remained stable
(12.6–13.2%), the increasing trend in mortality rate was asso-
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FIG. 1. Distribution of ten commonest
categories of microbes causing blood-
stream infections by gender and age
group, Finland, 2004–07.
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ciated with the increase in incidence. The average annualized
mortality rate increased by age, beginning in middle age and
was highest among the elderly (Table 2). Among people
‡25 years, mortality rates were 1.4-fold higher among men
than women (33.7 versus 24.5 per 100 000 population).
The ten most frequent categories of microbes were asso-
ciated with 78% of all BSI deaths (Table 3). Escherichia coli
and S. aureus were associated with 736 (17%) and 715 (16%)
of fatal episodes. The CFPs were 13% for gram-positive, 11%
for gram-negative, 14% for other bacterial and 35% for fungal
infections. The CFPs were highest for BSI caused by Pseudo-
monas aeruginosa (26%), polymicrobial episodes (21%), Entero-
coccus spp. (19%), and S. aureus (17%). Among patients
‡65 years, CFP was signiﬁcantly higher for BSI caused by
gram-positive bacteria compared with those caused by gram-
negative bacteria (1415/7301, 19% versus 1210/9357, 13%,
p <0.001); no difference was observed among patients
<65 years (718/8932, 8% versus 412/5288, 8%). For BSI
caused by gram-negative bacteria, CFP was signiﬁcantly larger
for male patients than female patients (862/6176, 14% versus
760/8469, 9%, p <0.001), but not in BSI caused by gram-posi-
tive bacteria (1246/9414, 13% versus 887/6819, 13%).
To study timing of death, the daily hazard of death follow-
ing BSI was estimated (Fig. 2); it was highest at day 1 (0.019/
person per day), and reached the expected hazard of death
TABLE 2. Mortality rate of blood-
stream infections at 30 days by age
and gender, Finland, 2004–07 Age group
(years)
Mortality of bloodstream infectionsa
(number of deaths)
Male to female
rate ratio 95% CIMale Female Total
<1 22.7 (27) 14.1 (16) 18.5 (43) 1.6 0.9–3.0
1–14 0.3 (5) 0.8 (14) 0.6 (19) 0.3 0.1–1.0
15–24 1.0 (13) 0.6 (7) 0.8 (20) 1.8 0.7–4.5
25–34 1.7 (22) 0.6 (8) 1.2 (30) 2.6 1.2–5.9
35–44 6.6 (96) 2.7 (38) 4.7 (134) 2.4 1.7–3.6
45–54 15.5 (240) 7.2 (111) 11.4 (351) 2.1 1.7–2.7
55–64 33.9 (482) 17.3 (252) 25.5 (734) 2.0 1.7–2.3
65–74 71.5 (596) 37.5 (372) 53.0 (968) 1.9 1.7–2.2
75–84 150.7 (680) 86.6 (671) 110.2 (1351) 1.7 1.6–1.9
‡85 323.8 (289) 158.9 (436) 199.3 (725) 2.0 1.8–2.4
All 23.8 (2450) 17.9 (1925) 20.8 (4375) 1.3 1.2–1.3
CI, conﬁdence interval.
aAverage annualized mortality rate (deaths per 100 000 population).
TABLE 3. Incidence and case fatal-
ity proportion of bloodstream
infections caused by ten common-
est categories of microbes at day
30, Finland, 2004–07
Categories of microbes
Incidencea
(number
of cases)
CFP, %
(number
of deaths)
Proportion of all
fatal episodes caused
by the category
Escherichia coli 44 (9190) 8.0 (736) 16.8
Staphylococcus aureus 20 (4231) 16.9 (715) 16.3
Coagulase-negative staphylococci 16 (3336) 11.1 (371) 8.5
Streptococcus pneumoniae 14 (2909) 10.0 (291) 6.7
Polymicrobial infections 10 (2029) 21.0 (426) 9.7
Klebsiella sp. 8 (1667) 14.0 (234) 5.3
Enterococcus spp. 7 (1418) 19.3 (274) 6.3
Group C and G streptococci 5 (1004) 9.2 (92) 2.1
Group B streptococcus 4 (791) 7.3 (58) 1.3
Pseudomonas aeruginosa 4 (759) 26.4 (200) 4.6
Other 29 (6139) 15.9 (978) 22.4
Total 159 (33473) 13.1 (4375)
CFP, case fatality proportion.
aAverage annualized incidence rate (episodes per 100 000 population).
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FIG. 2. Timing of deaths related to bloodstream infections, Finland,
2004–07. Observed and expected* daily hazard of death within
90 days. *Age-adjusted and sex-adjusted expected daily hazard of
death among the general Finnish population.
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among an age-adjusted and sex-adjusted Finnish population
(0.00064/person per day) at approximately 60 days. The
early peak in the hazard of death was most pronounced
among middle aged and older patients (the hazard of death
at day 1 was 0.008/person-day among patients aged <1 year,
0.003 in age group 1–34 years, 0.018 in 35–64 years, 0.022
in 65–84 years and 0.027 in patients aged >85 years). Of all
deaths, 32% (1380/4375) occurred during days 0–2. Among
patients aged <1 years, 49% of deaths within 30 days
occurred during days 0–2, whereas this was the case in 30–
35% among the other age groups. The proportion of early
deaths (days 0–2) was similar among female and male
patients (32% versus 31%). Of the deaths associated with
Streptococcus pneumoniae, 48% occurred early, of those
related to E. coli 36% were early, for S. aureus 23% were
early and for coagulase-negative staphylococci this value was
23%.
An estimated 934 average annual excess deaths within
30 days due to BSI were observed compared with the
expected 160 deaths among an age-adjusted and sex-adjusted
Finnish reference population, indicating an excess mortality
rate of 17.7 per 100 000 population.
Discussion
The data from this nationwide, population-based study indi-
cate that both incidence and mortality from BSI increased
signiﬁcantly during 2004–07. Considerable excess mortality
was attributable to BSI, particularly among the growing popu-
lation of older adults, underlining the importance of improv-
ing interventions to reduce risk and implementing speciﬁc
preventive measures such as preventing healthcare-associated
BSI and using available vaccines, such as pneumococcal vac-
cine against the major causes of BSI. Most BSI-related mor-
tality occurred within the ﬁrst month of infection. One-third
of deaths occurred within the ﬁrst few days after the diagno-
sis, emphasizing the importance of early identiﬁcation and
treatment of BSI.
The BSI rate increased by 14.3% during the 4-year study
period (from 147 to 168 per 100 000 population). Rates
were also substantially higher compared with our previous
study during 1995–2002 (125 per 100 000) which used data
from the same surveillance system [4]. Among the few previ-
ous population-based studies, higher rates have been
reported from Denmark [2] (153 per 100 000 in 1994), USA
[3] (190 per 100 000) and from England (189 per 100 000 in
2008) [5]. Differences in population demographics, health-
care-seeking behaviour and clinical practice, such as blood
culture sampling rate, may contribute to the reported differ-
ences. In our previous study, the increasing trend and regio-
nal differences in BSI rates in Finland were associated with
changes in blood-culturing activity, but not with changes in
causative agents of BSI [4]. Changes in blood-culturing meth-
odology may also play a role [12].
Over half of all BSI cases in our study and in previous
studies were 65 years or older [5,6]. We observed slightly
higher rates in male patients than female patients. Larger
gender differences have been reported in the USA and in
England in BSI [3,5] and in sepsis studies [13], especially
among patients aged over 60 years and among black persons.
In our study, rates were higher among working-age men
compared with women. Differences in prevalence of chronic
medical conditions and risk behaviours may contribute to
the observed gender differences. For example, smoking-
related chronic lung diseases and heavy alcohol use, which
are important risk factors for severe sepsis and invasive
pneumococcal infections, are more common among men
[14,15].
Escherichia coli and S. aureus were the most common aeti-
ologies of BSI in our study, consistent with other population-
based reports [3,5,6]. The incidence of E. coli was 44 per
100 000 in our study compared with 30–48 per 100 000 in
the previous population-based studies [3,5,16]. The incidence
of S. aureus was 20 per 100 000 in our study compared with
20–32 in previous studies) [3,17]. Consistent with previous
studies, the proportion of BSI due to E. coli was higher
among female patients [3,16]. The proportions of S. aureus
and Streptococcus pneumoniae were higher among male
patients in both our study and in previous studies [3,17,18].
To our knowledge, this is the ﬁrst study to report nation-
wide estimates of case fatality (13%) and mortality (20.8 per
100 000) for BSI within 30 days, describing the overall dis-
ease burden of BSI in the population. We found considerable
excess mortality from BSI (17.7 per 100 000) in the popula-
tion. Excess deaths were observed until approximately
60 days after BSI diagnosis, suggesting the need for standardi-
zation regarding the time-point to record outcome. In our
study, as in others, the mortality rate began to increase in
the middle aged, and 70% of fatal cases occurred in patients
aged 65 years or older [3,8,9]. Overall, we observed 1.4-fold
higher mortality rates in adult men than women, which may
be associated with a higher frequency of gram-positive BSI,
especially S. aureus. However, the difference may also reﬂect
different predisposing factors and care-seeking behaviour.
Escherichia coli and S. aureus caused an equal number of
the deaths and were associated with one-third of all fatal
outcomes. Whereas the rate of E. coli BSI was twice as high
as the rate of S. aureus BSI, the CFP of S. aureus BSI was
two-fold (8% in E. coli BSI versus 17% in S. aureus). Changes
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in overall rates of S. aureus BSI have been associated with
rates of methicillin-resistant S. aureus (MRSA) in England
[5,19], but not in Canada [17]. Signiﬁcant mortality and
morbidity was associated both with methicillin-susceptible
S. aureus (MSSA) and MRSA BSI in a recent European multi-
centre study [20]. As only 2.7% of S. aureus BSI cases were
caused by MRSA in Finland in 2007 (National Infectious Dis-
ease Register, unpublished data), it is unlikely that MRSA
contributes to the overall increase in BSI.
About one-third of the deaths occurred during the ﬁrst
2 days after the blood culture specimen conﬁrming BSI.
Some of the early deaths may be associated with delays in
seeking care, inaccurate initial diagnosis, or delay in or inap-
propriate treatment; others may be the result of severity of
disease at presentation in patients with predisposing factors
or virulent causative agents. The importance of delays in
administering antimicrobial therapy on the outcome of septic
shock is well established [21,22]. Although the choice of
empiric antibiotic therapy for blood-culture-conﬁrmed severe
sepsis was considered appropriate in 90% of cases in a
recent Finnish multicentre trial [14], inappropriate therapy
may be an important risk factor among nosocomial and
healthcare-associated BSI [23,24]. The choice of empiric anti-
biotic may be even more important in the future, if resis-
tance increases among common causes of BSI, such as
extended spectrum b-lactamase-producing E. coli strains.
Several limitations should be considered in interpreting
our ﬁndings. First, we did not have information on the
patients’ underlying medical conditions, including type and
severity of underlying illness or immunosuppression, which
may have inﬂuenced the observed gender differences and are
risk factors for fatal outcome. Second, we did not have infor-
mation on whether infection was the primary, immediate or
contributing factor of death. However, deaths occurring
shortly after the diagnosis of BSI are likely to be associated
with infection. Third, our database did not contain informa-
tion on whether the BSI was healthcare-associated or com-
munity-acquired, or clinical information such as the source of
infection and whether antimicrobial therapy was delayed or
inappropriate [8,9,22].
Our study documents the considerable burden of BSI, and
increasing incidence and mortality. To reduce this burden,
both general and microbe-speciﬁc interventions should be
developed. For E. coli and S. aureus, the most common causa-
tive agents for fatal BSI, infection control protocols are avail-
able for prevention of healthcare-associated BSI, especially
those related to surgery and devices. Studies by the US
CDC have shown that prevention of central line-associated
BSI has a profound impact on mortality [25]. In Finland,
enhanced surveillance of healthcare-associated BSI has been
conducted in selected hospitals since 1999, enabling identiﬁ-
cation of the source of infection (primary or secondary) and
monitoring of outcomes [26]. Only a few preventive mea-
sures, such as pneumococcal and inﬂuenza vaccinations, are
available for community-acquired BSI. Many deaths occurred
within the ﬁrst few days after the diagnosis, highlighting the
importance of improving access to health services, and
implementing treatment guidelines to identify and treat
patients with sepsis and BSI without delay.
Acknowledgements
We thank Teemu Mo¨tto¨nen for his assistance in collecting
the BSI data from the National Infectious Disease Register.
These data were presented in part at the second European
Scientiﬁc Conference on Applied Infectious Disease Epidemi-
ology (ESCAIDE), 2008, poster number 14.2.
Transparency Declaration
This work was supported by Pa¨ivikki and Sakari Sohlberg
Foundation. The authors have no conﬂicts of interest.
References
1. Yu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: ﬁnal data for
2006. Natl Vital Stat Rep 2009; 57: 1–134.
2. Madsen KM, Schonheyder HC, Kristensen B, Sorensen HT. Secular
trends in incidence and mortality of bacteraemia in a Danish County
1981–1994. APMIS 1999; 107: 346–352.
3. Uslan DZ, Crane SJ, Steckelberg JM et al. Age- and sex-associated
trends in bloodstream infections. A population-based study in Olm-
sted County, Minnesota. Arch Intern Med 2007; 167: 834–839.
4. Skogberg K, Lyytika¨inen O, Ruutu P, Ollgren J, Nuorti JP. Increase in
bloodstream infections in Finland, 1995–2002. Epidemiol Infect 2008;
136: 108–114.
5. Wilson J, Elgohari S, Livermore DM et al. Trends among pathogens
reported as causing bacteraemia in England 2004–2008. Clin Microbiol
Infect 2011; 17: 451–458.
6. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic
resistance of its pathogens reported in England and Wales between
1990 and 1998: trend analysis. BMJ 2000; 320: 213–216.
7. Curns AT, Holman RC, Sejvar JJ, Owings MF, Schonberger LB.
Infectious disease hospitalizations among older adults in the United
States from 1990 through 2002. Arch Intern Med 2005; 165: 2514–
2520.
8. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in
adults: a multicenter prospective survey in ICUs and wards of 24
hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit
Care Med 1996; 154 (3 Pt 1): 617–624.
9. Weinstein MP, Towns ML, Quartey SM et al. The clinical signiﬁcance
of positive blood cultures in the 1990s: a prospective comprehensive
evaluation of the microbiology, epidemiology, and outcome of bacter-
emia and fungemia in adults. Clin Infect Dis 1997; 24: 584–602.
CMI Skogberg et al. Burden of bloodstream infections E175
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E170–E176
10. Bouza E, Pe´rez-Molina J, Mun˜oz P. Report of ESGNI-001 and ESGNI-
002 studies. Bloodstream infections in Europe. Clin Microbiol Infect
1999; 5 (Suppl 2): 1–12.
11. Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern
GV. Epidemiology and outcome of nosocomial and community-onset
bloodstream infection. J Clin Microbiol 2003; 41: 3655–3660.
12. Søgaard M, Engebjerg MC, Lundbye-Christensen S, Schønheyder HC.
Changes in blood culture methodology have an impact on time
trends of bacteremia: a 26-year regional study. Epidemiol Infect 2011;
139: 772–776.
13. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sep-
sis in the United States from 1979 through 2000. N Engl J Med 2003;
348: 1546–1554.
14. Karlsson S, Varpula M, Ruokonen E et al. Incidence, treatment, and
outcome of severe sepsis in ICU-treated adults in Finland: the Finn-
sepsis study. Intensive Care Med 2007; 33: 435–443.
15. Klemets P, Lyytika¨inen O, Ruutu P, Ollgren J, Nuorti JP. Invasive
pneumococcal infections among persons with and without underlying
medical conditions: implications for prevention strategies. BMC Infect
Dis 2008; 8: 96.
16. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JDD. Inci-
dence, risk factors and outcomes of Escherichia coli bloodstream
infections in a large Canadian region. Clin Microbiol Infect 2008; 14:
1041–1047.
17. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream
infections: risk factors, outcomes, and the inﬂuence of methicillin
resistance in Calgary, Canada, 2000–2006. J Infect Dis 2008; 198:
336–343.
18. Lyytika¨inen O, Ruotsalainen E, Ja¨rvinen A, Valtonen V, Ruutu P.
Trends and outcome of nosocomial and community-acquired blood-
stream infections due to Staphylococcus aureus in Finland, 1995–2001.
Eur J Clin Microbiol Infect Dis 2005; 24: 399–404.
19. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology
of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005; 56:
455–462.
20. De Kraker ME, Wolkewitz M, Davey PG, Grundmann H, BURDEN
Study Group. Clinical impact of antimicrobial resistance in European
hospitals: excess mortality and length of hospital stay related to
methicillin-resistant Staphylococcus aureus bloodstream infections. Anti-
microb Agents Chemother 2011; 55: 1598–1605, Epub.
21. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C et al.
Timing of adequate antibiotic therapy is a greater determinant of out-
come than are TNF and IL-10 polymorphisms in patients with sepsis.
Crit Care 2006; 10: R111.
22. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before
initiation of effective antimicrobial therapy is the critical determinant of
survival in human septic shock. Crit Care Med 2006; 34: 1589–1596.
23. McDonald JR, Friedman ND, Stout JE, Sexton DJ, Kaye KS. Risk fac-
tors for ineffective therapy in patients with bloodstream infection.
Arch Intern Med 2005; 165: 308–313.
24. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I et al. Mortal-
ity and morbidity attributable to inadequate empirical antimicrobial
therapy in patients admitted to the ICU with sepsis: a matched
cohort study. J Antimicrob Chemother 2008; 61: 436–441.
25. Centers for Disease Control Prevention (CDC). Vital signs: central
line-associated blood stream infections—United States, 2001, 2008,
and 2009. Morb Mortal Wkly Rep 2011; 60: 243–248.
26. Lyytika¨inen O, Lumio J, Sarkkinen H et al. Nosocomial bloodstream
infections in Finnish hospitals during 1999–2000. Clin Infect Dis 2002;
35: e14–e19.
E176 Clinical Microbiology and Infection, Volume 18 Number 6, June 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E170–E176
